Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Eisai Inc. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research ...

Eisai Alzheimer's drug and clot buster seen as cause of brain hemorrhage death -analysis By Deena Beasley January 4, 20232:03 PM PSTUpdated January 4, 2023 ...

Eisai is continuing to advance care in Alzheimer’s disease via this multi-dimensional, yet targeted path to our ultimate goal: prevention and stopping progression.

Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer’s treatment Leqembi that may ultimately help bolster uptake of the drug. Weekly treatment with an experimental ...

Japanese drugmaker Eisai Co on Monday began its application process for its experimental drug for early Alzheimer's disease using an accelerated approval pathway, the same path that helped Eisai's ...

Eisai Inc. executives recently gave NJBIZ a tour of the company's new 15-story, 332,800-square-foot hub in Nutley.

Eisai Co. said a volunteer died while using the company’s experimental Alzheimer’s drug lecanemab in a clinical trial, but that it wasn’t clear if the death was directly caused by the drug.